Clinical efficacy of cefoperazone in obstetric and gynecologic infections

Compared with second-generation cephalosporins, cefoperazone, a third-generation cephalosporin, has demonstrated an extended antibacterial spectrum. In addition, it has a long serum half-life and requires only twice-a-day administration. In this study, 66 patients with clinically diagnosed obstetric and gynecologic infections were treated with cefoperazone, and 61 were evaluated for efficacy. An overall cure rate of 93% (57 patients) was achieved. In view of the excellent clinical response and convenience of twice-a-day administration, we conclude that cefoperazone is a clinically useful single agent for the initial empirical treatment of patients with obstetric and gynecologic infections.